YM598 in Patients With Rising PSA After Initial Therapy for Localized Prostate Cancer
June 6, 2012 updated by: Astellas Pharma Inc
The purpose of this study is to determine the optimal dosage of YM598 for slowing down disease progression in patients with rising PSA after initial therapy for localized prostate cancer.
Study Overview
Study Type
Interventional
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Brussels, Belgium
- University Clinic AZ
-
Brussels, Belgium
- University Clinic UCL St. Luc
-
-
-
-
-
Jablonec nad Nisou, Czech Republic
- Private Urology Out-patient Ward
-
Králové, Czech Republic
- Clinic of Urology, University Hospital
-
Olomouc, Czech Republic
- Clinic of Urology, University Hospital
-
Prague, Czech Republic
- Clinic of Urology, University Hospital
-
-
-
-
-
Paris, France
- Hôpital Bichat, service de Urology
-
-
-
-
-
Bad Homburg, Germany, 61348
- Haingasse 22
-
Dresden, Germany
- Klinik und Poliklinik für Urologie, Universitätsklinikum Carl-Gustav-Carus
-
Marburg, Germany
- Klinik u. Poliklinik für Urologie, Philipps Universität, Baldingerstraße
-
Marburg, Germany
- Krummbogen 15
-
-
-
-
-
Bydgoszcz, Poland
- Regional Hospital, Department of Urology
-
Gdansk, Poland
- MedSource Poland
-
Warszawa, Poland
- Bielanski Hospital, Department of Urology
-
Warszawa, Poland
- Oncology Center, Department of Urinary Tract Cancer
-
Wroclaw, Poland
- Medical University, Clinic of Urology
-
-
-
-
-
Corunna, Spain
- Complejo Hospitaliaro Juan Canalejo, Servicio de Urología
-
Madrid, Spain
- Fundacion Hospital Alcorcón, Servicio Urología
-
Madrid, Spain
- Hospital Universitario Principe de Asturias, Servicio de Urología, Ctra.
-
-
-
-
-
Bristol, United Kingdom
- Department of Urology, Bristol Royal Infirmary
-
Glasgow, United Kingdom
- Department of Urology, Gartnavel Hospital
-
Norwich, United Kingdom
- Department of Urology, Norfolk & Norwich Hospital
-
Taunton, United Kingdom
- Department of Urology, Taunton & Somerset Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Completion (Actual)
February 1, 2004
Study Registration Dates
First Submitted
December 3, 2002
First Submitted That Met QC Criteria
December 3, 2002
First Posted (Estimate)
December 4, 2002
Study Record Updates
Last Update Posted (Estimate)
June 7, 2012
Last Update Submitted That Met QC Criteria
June 6, 2012
Last Verified
June 1, 2012
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 598-CL-004
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.